Arax Advisory Partners’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.06M | Buy |
11,751
+10,662
| +979% | +$893K | 0.01% | 1176 |
|
|
2026
Q1 | $87K | Sell |
1,089
-463
| -30% | -$38.2K | ﹤0.01% | 1457 |
|
|
2025
Q4 | $132K | Sell |
1,552
-48,893
| -97% | -$4.01M | ﹤0.01% | 1205 |
|
|
2025
Q3 | $3.92M | Buy |
50,445
+49,342
| +4,473% | +$3.86M | 0.06% | 285 |
|
|
2025
Q2 | $88.2K | Sell |
1,103
-16
| -1% | -$1.19K | ﹤0.01% | 988 |
|
|
2025
Q1 | $81.1K | Sell |
1,119
-583
| -34% | -$41.7K | 0.01% | 788 |
|
|
2024
Q4 | $126K | Buy |
1,702
+724
| +74% | +$50.7K | 0.01% | 605 |
|
|
2024
Q3 | $64.5K | Buy |
978
+99
| +11% | +$7.19K | 0.01% | 623 |
|
|
2024
Q2 | $81.2K | Buy |
879
+244
| +38% | +$21.6K | 0.01% | 514 |
|
|
2024
Q1 | $60.7K | Buy |
635
+10
| +2% | +$840 | 0.01% | 459 |
|
|
2023
Q4 | $47.7K | Sell |
625
-11
| -2% | -$765 | 0.01% | 487 |
|
|
2023
Q3 | $44.1K | Buy |
636
+474
| +293% | +$38.1K | 0.01% | 482 |
|
|
2023
Q2 | $15.3K | Buy |
162
+7
| +5% | +$608 | ﹤0.01% | 630 |
|
|
2023
Q1 | $12.8K | Sell |
155
-8
| -5% | -$629 | ﹤0.01% | 651 |
|
|
2022
Q4 | $12.2K | Sell |
163
-310
| -66% | -$23.9K | ﹤0.01% | 622 |
|
|
2022
Q3 | $39K | Buy |
473
+1
| +0.2% | +$96 | 0.01% | 465 |
|
|
2022
Q2 | $45K | Buy |
472
+24
| +5% | +$2.48K | 0.01% | 440 |
|
|
2022
Q1 | $53K | Sell |
448
-27
| -6% | -$3.03K | 0.01% | 443 |
|
|
2021
Q4 | $62K | Hold |
475
| – | – | 0.01% | 432 |
|
|
2021
Q3 | $54K | Sell |
475
-58
| -11% | -$6.62K | 0.01% | 442 |
|
|
2021
Q2 | $55K | Buy |
+533
| New | +$50.2K | 0.01% | 449 |
|
|
2020
Q4 | $49K | Hold |
540
| – | – | 0.01% | 415 |
|
|
2020
Q3 | $43K | Sell |
540
-160
| -23% | -$12.5K | 0.01% | 399 |
|
|
2020
Q2 | $48K | Sell |
700
-2,000
| -74% | -$142K | 0.01% | 373 |
|
|
2020
Q1 | $170K | Hold |
2,700
| – | – | 0.04% | 167 |
|
|
2019
Q4 | $210K | Hold |
2,700
| – | – | 0.06% | 151 |
|
|
2019
Q3 | $198K | Hold |
2,700
| – | – | 0.06% | 155 |
|
|
2019
Q2 | $166K | Buy |
+2,700
| New | +$163K | 0.06% | 164 |
|
|
2018
Q4 | $245K | Buy |
4,803
+2,799
| +140% | +$142K | 0.1% | 105 |
|
|
2018
Q3 | $116K | Buy |
2,004
+1,524
| +318% | +$74.5K | 0.05% | 179 |
|
|
2018
Q2 | $23K | Buy |
480
+138
| +40% | +$6.44K | 0.01% | 284 |
|
|
2018
Q1 | $15K | Sell |
342
-75
| -18% | -$3.26K | 0.01% | 295 |
|
|
2017
Q4 | $15K | Hold |
417
| – | – | 0.01% | 299 |
|
|
2017
Q3 | $15K | Buy |
417
+15
| +4% | +$572 | 0.01% | 296 |
|
|
2017
Q2 | $16K | Hold |
402
| – | – | 0.01% | 316 |
|
|
2017
Q1 | $12K | Hold |
402
| – | – | 0.01% | 314 |
|
|
2016
Q4 | $13K | Buy |
+402
| New | +$13K | 0.01% | 296 |
|
Other funds holding EW
Arax Advisory Partners's EW Position: Q2 2026 in Review
Arax Advisory Partners increased its Edwards Lifesciences (EW) stake by 979% in Q2 2026, buying an estimated $893K and bringing the position to 11,751 shares worth $1.06M. The position accounts for 0.01% of the portfolio, ranked #1176.
Arax Advisory Partners first reported a position in EW in Q4 2016 and has held it in 37 quarters since. The position peaked at $3.92M in Q3 2025. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Arax Advisory Partners held 11,751 shares of Edwards Lifesciences worth $1.06M as of Q2 2026.
- Arax Advisory Partners bought 10,662 Edwards Lifesciences shares in Q2 2026, an estimated $893K.
- Edwards Lifesciences made up 0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #1176 holding.
- Arax Advisory Partners first reported a position in Edwards Lifesciences in Q4 2016 and has held it in 37 quarters since.
- Arax Advisory Partners's Edwards Lifesciences position peaked at $3.92M in Q3 2025.
- 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.